Summary
The application of prostate-specific antigen (PSA) in the screening and diagnosis of prostate cancer (PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26 (MMP26) is a member of matrix metalloproteinases (MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay (ELISA) in 160 subjects including PCa group (n=80), benign prostatic hyperplasia (BPH) group (n=40) and control group (n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014,64(4):252–271
Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol, 2009,9:14
Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol, 2011,185(5):1650–1655
Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/mL: systematic review and meta-analysis. Eur Urol, 2005,48(3):386–399
Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 1994,151(5):1283–1290
Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med, 1997,126(5):394–406
Yang CC, Sun SS, Lin CY, et al. Differentiation of prostate cancer and benign prostatic hyperplasia: the clinical value of 201Tl SPECT—a pilot study. Ann Nucl Med, 2003,17(7):521–524
Amalinei C, Caruntu ID, Giusca SE, et al. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol, 2010,51(2):215–228
Rita Balistreri C, Allegra A, Crapanzano F, et al. Matrix metalloproteinases (MMPs), their genetic variants and miRNA in mitral valve diseases: potential biomarker tools and targets for personalized treatments. J Heart Valve Dis, 2016,25(4):463–474
Feng YH, Wu LS, Su J, et al. Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese), 2013,21(5):1167–1172
Marchenko GN, Ratnikov BI, Rozanov DV, et al. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J, 2001,356(Pt 3):705–718
Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer, 2003,97(1):79–89
Yang XH, Richardson AL, Torres-Arzayus MI, et al. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res, 2008,68(9):3204–3213
Hu Q, Yan C, Xu C, et al. Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients. Tumour Biol, 2014,35(4):3569–3574
Xu X, Ma J, Li C, et al. Regulation of chondrosarcoma invasion by MMP26. Tumour Biol, 2015,36(1):365–369
Zhang Y, Zhao H, Wang Y, et al. Non-small cell lung cancer invasion and metastasis promoted by MMP-26. Mol Med Rep, 2011,4(6):1201–1209
Zhao YG, Xiao AZ, Ni J, et al. Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells. Ai Zheng, 2009,28(11):1168–1175
Khamis ZI, Iczkowski KA, Man YG, et al. Evidence for a proapoptotic role of matrix metalloproteinase-26 in human prostate cancer cells and tissues. J Cancer, 2016,7(1):80–87
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 1991,324(17):1156–1161
Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med, 2012,366(11):981–990
Romero Otero J, Garcia Gomez B, Campos Juanatey F, et al. Prostate cancer biomarkers: an update. Urol Oncol, 2014,32(3):252–260
Wang T, Xie ZP, Huang ZS, et al. Total triterpenoids from Ganoderma Lucidum suppresses prostate cancer cell growth by inducing growth arrest and apoptosis. J Huazhong Univ Sci Technol [Med Sci], 2015,35(5):736–741
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by grants from the National Nature Science Foundations of China (No. 81372801, No. 81472783, No. 81630060, No. 81230083 and No. 81272422), and the National Basic Research Program of China (No. 2015CB553003).
Rights and permissions
About this article
Cite this article
Cheng, T., Li, F., Wei, R. et al. MMP26: A potential biomarker for prostate cancer. CURR MED SCI 37, 891–894 (2017). https://doi.org/10.1007/s11596-017-1823-8
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-017-1823-8